Neuroprotection of Radiosensitive Juvenile Mice by Ultra-High Dose Rate FLASH Irradiation
Authors:
- Yasaman AlaghbandYAYasaman Alaghband
- Samantha N. CheeksSCSamantha N. Cheeks
- Barrett D. AllenBABarrett D. Allen
- Pierre Montay-GruelPMPierre Montay-Gruel
- Ngoc-Lien DoanNDNgoc-Lien Doan
- Benoit PetitBPBenoit Petit
- Patrik Goncalves JorgePJPatrik Goncalves Jorge
- Erich GiedzinskiEGErich Giedzinski
- Munjal M. AcharyaMAMunjal M. Acharya
- Marie-Catherine VozeninMVMarie-Catherine Vozenin
- Charles L. LimoliCharles L. Limoli
Open Access
Abstract
Major advances in high precision treatment delivery and imaging have greatly improved the tolerance of radiotherapy (RT); however, the selective sparing of normal tissue and the reduction of neurocognitive side effects from radiation-induced toxicities remain significant problems for pediatric patients with brain tumors. While the overall survival of pediatric patients afflicted with medulloblastoma (MB), the most common type primary brain cancer in children, remains high (≥80%), lifelong neurotoxic side-effects are commonplace and adversely impact patients’ quality of life. To circumvent these clinical complications, we have investigated the capability of ultra-high dose rate FLASH-radiotherapy (FLASH-RT) to protect the radiosensitive juvenile mouse brain from normal tissue toxicities. Compared to conventional dose rate (CONV) irradiation, FLASH-RT was found to ameliorate radiation-induced cognitive dysfunction in multiple independent behavioral paradigms, preserve developing and mature neurons, minimize microgliosis and limit the reduction of the plasmatic level of growth hormone. The protective “FLASH effect” was pronounced, especially since a similar whole brain dose of 8 Gy delivered with CONV-RT caused marked reductions in multiple indices of behavioral performance (objects in updated location, novel object recognition, fear extinction, light-dark box, social interaction), reductions in the number of immature (doublecortin+) and mature (NeuN+) neurons and increased neuroinflammation, adverse effects that were not found with FLASH-RT. Our data point to a potentially innovative treatment modality that is able to spare, if not prevent, many of the side effects associated with long-term treatment that disrupt the long-term cognitive and emotional well-being of medulloblastoma survivors.Keywords
Funding Information
- undefined <span style="color:gray;font-size:10px;">undefined</span> (Synergia grant from the FNS CRS II5_186369)
- National Institute of Neurological Disorders and Stroke (NS089575)
This publication has 73 references indexed in Scilit:
- Radiation-induced vascular changes in the intracranial irradiation field in medulloblastoma survivors: An MRI studyRadiotherapy and Oncology, 2019
- Pediatric Brain TumorsNeurologic Clinics, 2018
- Evolution of cerebral microbleeds after cranial irradiation in medulloblastoma patientsNeurology, 2017
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summaryActa Neuropathologica, 2016
- Management of Pediatric and Adult Patients with MedulloblastomaCurrent Treatment Options in Oncology, 2014
- Medulloblastoma: Progress over timeJournal of Medical Imaging and Radiation Oncology, 2012
- Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomesNeuro-Oncology, 2011
- Cognitive Consequences of the Treatment of Medulloblastoma Among ChildrenPediatric Neurology, 2011
- Risks of Young Age for Selected Neurocognitive Deficits in Medulloblastoma Are Associated With White Matter LossJournal of Clinical Oncology, 2001
- Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999